Compare YRD & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | YRD | OVID |
|---|---|---|
| Founded | 2012 | 2014 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 321.4M | 365.5M |
| IPO Year | 2015 | 2017 |
| Metric | YRD | OVID |
|---|---|---|
| Price | $2.20 | $2.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $4.60 |
| AVG Volume (30 Days) | 174.0K | ★ 4.6M |
| Earning Date | 03-19-2026 | 05-12-2026 |
| Dividend Yield | ★ 22.00% | N/A |
| EPS Growth | N/A | ★ 3.90 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,252,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $22.53 |
| P/E Ratio | $1.86 | ★ N/A |
| Revenue Growth | N/A | ★ 1181.27 |
| 52 Week Low | $1.58 | $0.27 |
| 52 Week High | $7.68 | $3.11 |
| Indicator | YRD | OVID |
|---|---|---|
| Relative Strength Index (RSI) | 47.28 | 64.63 |
| Support Level | $1.58 | $1.31 |
| Resistance Level | $4.40 | $3.11 |
| Average True Range (ATR) | 0.11 | 0.22 |
| MACD | 0.11 | 0.03 |
| Stochastic Oscillator | 93.85 | 72.81 |
Yiren Digital Ltd is an AI-powered platform providing a comprehensive suite of financial and lifestyle services in China. Its mission is to elevate customers' financial well-being and enhance their quality of life by delivering digital financial services, tailor-made insurance solutions, and premium lifestyle services. The company supports clients at various growth stages, addressing financing needs arising from consumption and production activities, while aiming to augment the overall well-being and security of individuals, families, and businesses.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.